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Radiologic breast density is one of the predictive factors for breast cancer and the extent of the density is directly related to
postmenopause. However, some patients have dense breasts even during postmenopause. This condition may be explained by
the genes that codify for the proteins involved in the biosynthesis, as well as the activity and metabolism of steroid hormones.
They are polymorphic, which could explain the variations of individual hormones and, consequently, breast density. The
constant need to find markers that may assist in the primary prevention of breast cancer as well as in selecting high risk patients
motived this study. We determined the influence of genetic polymorphism of CYP17 (cytochrome P450c17, the gene involved
in steroid hormone biosynthesis), GSTM1 (glutathione S-transferase M1, an enzyme involved in estrogen metabolism) and
PROGINS (progesterone receptor), for association with high breast density. One hundred and twenty-three postmenopausal
patients who were not on hormone therapy and had no clinical or mammographic breast alterations were included in the present
study. The results of this study reveal that there was no association between dense breasts and CYP17 or GSTM1. There was
a trend, which was not statistically significant (P = 0.084), towards the association between PROGINS polymorphism and dense
breasts. However, multivariate logistic regression showed that wild-type PROGINS and mutated CYP17, taken together,
resulted in a 4.87 times higher chance of having dense breasts (P = 0.030). In conclusion, in the present study, we were able to
identify an association among polymorphisms, involved in estradiol biosyntheses as well as progesterone response, and
radiological mammary density.
Key words: Mammography; 17-alpha hydroxylase steroid; Glutathione transferase; Progesterone receptor;
Genetic polymorphism
Publication supported by FAPESP.
Received May 2, 2008. Accepted February 11, 2009
Introduction
Radiological breast density is influenced by the hormo-
nal changes that occur throughout the life of women and is
considered to be one of the most important independent
risk factors for breast cancer (1-5). Generally, women with
high breast density (more than 50% of glandular tissue)
have a 4 to 6 times higher risk to develop breast cancer (4)
than women with fatty breasts. While there is convincing
evidence for the independent association of breast density
with breast cancer risk, it is perhaps the most underesti-
mated and underused risk factor when it comes to causal
studies of breast cancer. Actually, it has not been included
as a parameter in the traditional risk calculation models
such as that of Gail et al. (6) and more recently in the model
proposed by Rockhill et al. (7).
There have been numerous studies linking mammo-
graphic breast density to factors associated with exposure
to endogenous and exogenous steroid hormones such as
age, menopausal status, parity, body mass index (BMI),
and the use of hormone therapy (4).
For instance, the luteal phase of the menstrual cycle
exposes the breast tissue to estradiol and progesterone
and this causes an increase in breast density (8). Pre-
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menopausal women also have denser breasts compared
with postmenopausal women. Increase in breast density
after menopause has been attributed to alterations in
growth factor (9), epidemiologic factors (10) and genetic
factors (11), but there is no conclusive data to support any
of these. Based on the established function of endogenous
steroids for maintaining and developing breast tissue,
individual variation in breast density may be due, in part, to
polymorphisms in steroid hormone biosynthesis, metabo-
lism and signaling genes (3).
Recently, the genetic basis of changes in hormone
levels has been recognized as an important factor for
breast cancer risk. According to some studies, polymor-
phisms in certain genes could affect breast cancer risk
through differences in breast density (12,13). Recent stud-
ies have proposed that cytochrome P450c17 (CYP17,
involved in biosynthesis), glutathione S-transferase M1
(GSTM1, which also has an important function in estrogen
metabolism) and progesterone receptor gene polymor-
phism (PROGINS) are potential candidate biomarkers for
breast cancer (14,15). It is thus important to seek markers
that assist in the identification of high-risk persons on the
basis of breast density, which is determined by genetic
individuality.
Patients and Methods
Study population
Eligible cases consisted of 123 women with no previ-
ous history of hormone replacement therapy, treated at the
Climacteric Section, Gynecology Department at the Fede-
ral University of São Paulo from August to December
2006. As inclusion criteria, no more than 5 years since the
beginning of menopause, serum follicle-stimulating hor-
mone (FSH) >30 μL/mL, estradiol <50 pg/mL, should not
present hepatic, kidney and endocrine disease, nor severe
hypertension, and with no family history of breast cancer
and a class 1 or 2 mammogram exam (BI-RADS, Breast
Imaging and Data System, American College of Radiolo-
gists). All women were selected after the approval of the
research plan by the University Ethics Committee and
written informed consent was obtained from all partici-
pants.
Buccal swab collection and DNA extraction
Buccal swab samples were obtained using a Cytobrush
type cell collector that was rubbed against the buccal mu-
cosa and were placed in a Falcon tube containing Tris-EDTA
buffer and stored at -80°C. DNA extraction was performed
according to the Amersham Pharmacia GFX® Kit protocol for
buccal cells and quantified spectrophotometrically at 260
nm using a Genesys 5 model Spectronic spectrophotometer
(Spectronic Instruments, USA).
Genotyping
Polymerase chain reaction (PCR) fragments were gen-
erated using the following primers: GSTM1 forward (F): 5' -
GAA CTC CCT GAA AAG CTA AAG C - 3' and GSTM1
reverse (R): 5' - GTT GGG CTC AAA TAT ACG GTG G - 3;
CYP17 F: 5' - CAT TCG CAC TCT GGA GTC - 3' and
CYP17 R: 5' - AGG CTC TTG GGG TAC TTG - 3; PROGINS
F: 5' - GGC AGA AAG CAA AAT AAA AAG A - 3' and
PROGINS R: 5' - AAA GTA TTT TCT TGC TAA ATG TC - 3'.
PCR was carried out using standard procedures. Briefly
20-μL aliquots containing approximately 70 ng Genomic
DNA, 25 pmols primer, 1X reaction buffer, 100 μM dNTPs
and one unit of Taq polymerase. The reaction was per-
formed for 35 cycles at 55°C annealing temperature to all
primer sets.
After PCR amplification, the polymorphisms were as-
sayed by restriction fragment length polymorphism. The
CYP17 PCR product was incubated with 3 units of specific
restriction enzyme MspA1I (MBI Fermentas) at 37°C for
3 h. The resulting fragments were electrophoresed on a
2% agarose gel, stained with ethidium bromide and visual-
ized under UV (Figures 1-3).
We used only PCR to genotype subjects for GSTM1
and PROGINS. Homozygous deletion variants of GSTM1
did not result in an amplification fragment (16). On the
other hand, the presence of the gene resulted in a 268-bp
amplicon. The wild-type allele for PROGINS, defined as
the absence of insertion according to Rowe et al. (17,18),
generated a 149-bp fragment and its polymorphic allele
Figure 1. Gel electrophoretic pattern for polymorphism in
GSTM1. Lane M = 100-bp marker; lanes 1, 3, 4, 5, 7 = GSTM1
present in samples (268 bp); lanes 2 and 6 = null GSTM1
samples.
M 1 2 3 4 5 6 7
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generated a 455-bp fragment. Alleles were classified on
the basis of the presence of amplified fragments of corre-
sponding size using standard markers.
Mammograph analysis
The mammographs were analyzed in medial-lateral
view in order to visualize a greater quantity of parenchyma.
The left medial-lateral view was chosen by convention.
The films were assessed using subjective and objective
analysis.
In the subjective part of the analysis, the mammary
density was classified according to the ACR-BIRADS (19)
into four categories: D1, mainly lipo-substituted breasts (0-
25% of parenchymal tissue); D2, partially lipo-substituted
breasts (25-50% of parenchymal tissue); D3, moderately
dense breasts (50-75% of parenchymal tissue); D4, ex-
tremely dense breasts (>75% of parenchymal tissue). Due
to the subjectivity associated with the method the films
were assessed and classified by two independent trained
observers. Kappa statistics (κ) was applied, according to
Landis and Koch (20), to measure the agreement between
two observers. Due to the reduced number of women, the
initial 4 groups (D1, D2, D3, and D4) were reduced to two
groups (D1 + D2 and D3 + D4) for further analysis (see
Table 1).
The objective analysis was carried out to obtain repro-
ducible values for mammary density. The images were
digitized using a CX312 T scanner (Radiographic Digital
Imaging Compton, USA) and stored as tagged image file
(tif) format. A tif image is composed of small descriptor
blocks containing offsets into the file, which point to the
actual pixel image data, and there is no loss in image
quality. The digitized images were analyzed with the aid of
Figure 2. Gel electrophoresis showing the polymorphic patterns
obtained for CYP17. Lane M = 100-bp marker; lanes 1 and 5 = wild
homozygote samples for the CYP17 polymorphism (419 bp); lanes
2, 3, and 7 = mutated homozygote samples for the CYP17 poly-
morphism (295 and 124 bp); lanes 4 and 6 = heterozygote samples
for the CYP17 polymorphism (419, 295 and 124 bp).
Figure 3. Gel electrophoresis showing the polymorphic patterns
obtained for PROGINS. Lane M = 100-bp marker; lanes 1, 2, and
3 = PROGINS heterozygote sample (455 and 149 bp); lane 4 =
negative control of the reaction; lane 5 = wild PROGINS sample
(149 bp).
M 1 2 3 4 5
M 1 2 3 4 5 6 7
Table 1. Frequency of the breast density classification according
to individual observer analysis and software analysis (Photo-
shop) by BI-RADS criteria and two subgroups.
Category BI-RADS New subgroups
D1 D2 D3 D4 D1 + D2 D3 + D4
Observer 1 35 46 27 8 81 35
Observer 2 29 52 28 7 81 35
Photoshop 28 54 27 7 82 34
D1 = 0-25% parenchymal ti *ssue; D2 = 25-50% parenchymal
tissue; D3 = 50-75% parenchymal tissue; D4 = 75-100% paren-
chymal tissue. New subgroups: non-dense breasts (D1 + D2);
dense breasts (D3 + D4). Obs = observer. Inter-rater agreement
(kappa index, κ) was used to evaluate the agreement in the
density classification: Obs1 x Obs2 (BI-RADS criteria) κ = 0.91;
Obs1 x software (BI-RADS criteria) κ = 0.834; Obs2 x software
(BI-RADS criteria) κ = 0.91 (P < 0.001); Obs1 x Obs2 (new
subgroup) κ = 1; Obs x software (new subgroup) κ = 0.942 (P <
0.001).
the Photoshop 6.0 software (Figure 4). The density was
calculated using the gray scale histogram tool. Mammary
density was normalized using the following equation: DM =
AD / AT x 100, where DM is the mammary density, AD is
the dense area, and AT is the total area (see Table 1).
Statistical analysis
Initially, all variables were analyzed descriptively. The
quantitative variables were analyzed by observation of the
minimum and maximum values, and by calculation of
medians, means and standard deviations. Relative and
absolute frequencies were calculated for the qualitative
variables. Inter-rater agreement (kappa) index was used to
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Table 2. Patient characteristics according to the subclassifica-
tion of breast densities.
D1 + D2 D3 + D4
(N = 86) (N = 37)
Ageb 52.45 ± 4.49 51.32 ± 4.57
BMIb 28.22 ± 4.19 24.56 ± 3.73*
Smokingc (number of patients) 18 (20.9%) 10 (27.0%)
Parityd 3.14 ± 1.71 2.24 ± 1.32*
Age at first deliverya,b 22.84 ± 4.60 24.58 ± 5.31
Breast feedingc 75 (87.2%) 31 (83.8%)
Age at menarcheb 13.03 ± 1.60 14.05 ± 1.84*
Age at menopauseb 48.60 ± 4.51 47.59 ± 4.52
Time of menopaused 3.85 ± 3.35 3.73 ± 3.51
Hormone influence timeb (years) 35.57 ± 4.60 33.54 ± 4.41
D1 = 0-25% parenchymal tissue; D2 = 25-50% parenchymal
tissue; D3 = 50-75% parenchymal tissue; D4 = 75-100% paren-
chymal tissue; D1 + D2 = non-dense; D3 + D4 = dense; BMI =
body mass index. aSeven cases of parity were equal to zero (3
cases in D1 + D2 and 4 cases in D3 + D4). Statistical analysis
was performed using the bStudent t-test, the cchi-square test,
and the dMann-Whitney non-parametric test (P < 0.007).
Figure 4. Breast density calculation on a lipo-substituted breast. Panel A, Selection of the total area of the breast, which is equivalent
to 1,559,596 pixels. Panel B, Selection of the dense area, which is equivalent to 194,861 pixels the gray scale. Thus, there is 12%
dense area in this breast.
A B
Table 3. Polymorphism patterns and their distribution according
to the subclassification of breast densities.
Category D1 + D2 (N = 86) D3 + D4 (N = 37)
CYP17
Heterozygote 47 (54.7%) 18 (48.7%)
Mutated 10 (11.6%) 9 (24.3%)
Wild 29 (33.7%) 10 (27.0%)
PROGINS
Heterozygote 20 (23.3%) 4 (10.8%)
Wild 66 (76.7%) 33 (89.2%)
GSTM1
Null 22 (25.6%) 7 (18.9%)
Present 64 (74.4%) 30 (81.1%)
Data are reported as number with percent in parentheses. D1 +
D2 = non-dense; D3 + D4 = dense; CYP17 = cytochrome
P450c17; PROGINS = progesterone receptor gene polymor-
phism; GSTM1 = glutathione S-transferase M1.
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evaluate the agreement in the density classification. Stu-
dent t-test was used to analyze the equality hypothesis
between the two groups. When the supposition of normal-
ity of the data was rejected, the Mann-Whitney non-para-
metric test was used. The chi-square test was used to test
the group homogeneity of proportions. The logistic regres-
sion model was used for the multivariate study of the
factors. Through these means, the confidence intervals for
odds ratio were obtained. The significance level used for
the tests was 5%.
Results
The characteristics of the women who participated in
the study are summarized in Table 2. BMI, parity and age
at menarche were statistically significant when was com-
pared between groups of mammary density. Patterns of
polymorphisms are illustrated in Figures 1, 2, 3 and the
results of the association between polymorphisms and
mammary density are presented in Table 3. Polymor-
phisms in CYP17 and GSTM1 are clearly not associated
with breast density. This result is different from the litera-
ture that afirms that GSTM1 homozygous deletion was
associated with high mammographic density (21) but agrees
with CYP17 findings in which Warren et al. (22) studied 15
single nucleotide polymorphisms (SNP) in the CYP17,
CYP19, EDH17B2, SHBG, COMT, and CYP1B1 genes
and none of the SNPs, including those shown previously to
be associated with estradiol or SHBG, showed significant
associations with breast density. The same thing occurred
with PROGINS when analyzed in a isolated form (P =
0.110). However, the multivariate logistic regression anal-
ysis model built using the variables BMI, PROGINS, parity,
and age at menarche helped delineate the association of
these variables to breast density. The results of the regres-
sion analysis are summarized in Table 4. Analysis of the
variables also revealed that there was a negative correla-
tion between BMI and breast density as well as between
parity and breast density, thus the greater the BMI and
parity, the lesser the probability of dense breast. Age at
menarche, on the other hand, presented a positive correla-
tion with breast density, i.e., the greater the age at me-
narche, the greater the probability of dense breasts. The
association of PROGINS with breast density was not sig-
nificant. Amplification of the sample will be necessary to
define its predictive power.
To further understand the multi-factorial nature of breast
density, additional variables in the form of the three studied
polymorphisms (CYP17, GSTM1, and PROGINS) were
included in the regression model. The results are summa-
rized in Table 5.
Table 5. Odds ratio, 95% confidence interval and P value of the
multivariate logistic and regression model for dense breast, in-
cluding the statistically relevant variables (BMI, parity, age at
menarche).
Variables Odds 95%CI P
ratio
BMI 0.80 0.70-0.90 <0.001
PROGINS (wild x heterozygote) 0.25 0.06-1.06 0.060
GSTM1 (null x present) 1.09 0.34-3.52 0.881
CYP17 (wild x heterozygote) 1.36 0.47-3.96 0.568
CYP17 (wild x mutated) 4.02 0.94-17.20 0.061
Parity 0.62 0.43-0.89 0.011
Age at menarche 1.40 1.06-1.85 0.018
The three possible gene polymorphism patterns are included.
BMI = body mass index; PROGINS = progesterone receptor
gene polymorphism; GSTM1 = glutathione S-transferase M1;
CYP17 = cytochrome P450c17.
Table 6. Odds ratio, 95% confidence interval and P value of the
multivariate logistic and regression model, including the statisti-
cally relevant variables and the simultaneous presence of wild
PROGINS and mutated CYP17.
Variables Odds ratio 95%CI P
BMI 0.79 0.70-0.90 <0.001
Parity 0.64 0.45-0.91 0.014
Age at menarche 1.39 1.05-1.83 0.020
PROGINS and CYP17 4.87 1.16-20.39 0.030
Others* 1.00 - -
BMI = body mass index; PROGINS = progesterone receptor
gene polymorphism; CYP17 = cytochrome P450c17. *Wild and
mutated.
An additional analysis including both wild-type
PROGINS and the mutated CYP17 was created and built
into the model. The odds ratio values, following the use of
this new genotype association, are summarized in Table 6.
Table 4. Multivariate logistic regression analysis model of BMI,
PROGINS, parity, and age at menarche variable for dense
breast.
Variables Odds ratio 95%CI
BMI 0.81 0.71-0.91*
PROGINS 0.31 0.08-1.17
Parity 0.63 0.44-0.90*
Age at menarche 1.43 1.09-1.86*
BMI = body mass index. PROGINS = progesterone receptor
gene polymorphism.
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The results are indicative of the fact that women harboring
wild-type PROGINS and mutated CYP17 have a 4.87
chance to exhibit dense breasts compared with those who
do not present this combination.
Discussion
In the present study, we were able to identify genetic
variations in CYP17 and in progesterone receptor genes
as potential markers for high radiological breast density in
menopausal women when both were present. We also
confirmed a previous positive association of high breast
density and variables such as BMI, parity and age at first
birth. Almost 70% of our sample presented non-dense
breasts after 1-5 years of menopause status. These women,
besides having higher BMI and greater parity, also had
younger age at the first birth, which is a stronger variable in
postmenopausal women (23). From the genetic point of
view, there are conflicting results in the literature regarding
breast density. Indeed, several other researchers have
found discrepant results when trying to associate breast
density with genetic variables (13,14,24).
To the best of our knowledge, we are the first to find
associations between progesterone receptor variants,
CYP17 and radiologic breast density. Indeed, our results
regarding the progesterone receptor gene might be one of
the reasons why, in the postmenopausal estrogen/proges-
tin interventions (PEPI) trials (25), it was found that 8% of
estrogen-only users and about 19-24% of estrogen-pro-
gestin users had increased breast density, compared with
a 2% increase in the placebo group. Their results of a 13-
fold increased risk for denser breasts clearly points to the
importance of progesterone.
Progesterone therapy has been shown to vary based
on the accessibility of the functional progesterone receptor
(PR) (26). The PR polymorphism, known as PROGINS,
consists of a 306-bp Alu insertion in intron G in the hor-
mone-binding domain encoding region of the gene (18).
Human progesterone receptor (hPR) gene uses separate
promoters and translation start sites to produce two iso-
forms hPR-A and hPR-B with varying transcriptional activ-
ity and the presence of PROGINS might be associated with
an imbalance in the production of these two isoforms (26).
We speculate that these results support the view that the
presence of the hPR-A isoform could lead to a greater
mitogenic action of progesterone resulting in greater breast
density (25).
Glutathione S-transferases (GSTs) that catalyze gluta-
thione-mediated reduction of exogenous and endogenous
electrophiles have broad and sometimes overlapping sub-
strate specificities (27). The other focus of our study was
the polymorphism located in the CYP17 gene, which is
responsible for the production of one enzyme involved in
the biosynthesis of steroid hormones. This simple T→C
change in the 5' promoter region of CYP17 is reported to
increase estradiol levels and has also been investigated
for its risk in breast cancer development, with conflicting
results (28). As an isolated finding, our results did not
identify CYP17 as a marker for breast density; however,
after multivariate logistic regression, our results identified
wild-type PROGINS and the polymorphic form of CYP17
as potential markers to determine a 4.87 greater chance of
having dense breasts (P = 0.03). According to these find-
ings, we suggest that breast density might be related to an
increased estradiol biosynthesis, due to CYP17 polymor-
phism, followed by a strong progesterone action deter-
mined by the hPR-A isoform. This biochemical scenario
would then be responsible for an increase of breast den-
sity.
The results of our study suggest the importance of
using genetic analysis in the determination of breast den-
sity and that there is a complex picture of the associations
between genes. It could open up new approaches to
identifying patients at risk and in the future, it might permit
a more rational choice for selecting patients who would
really benefit from hormonal therapy.
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